The Use of intravenous Antibiotics at the Onset of Neutropenia in Patients Receiving Hematopoietic Stem Cell Transplants: A “Pre-Emptive” Strategy  by Hamadah, A. et al.
Poster Session I S279Invasive mold infections (IMI) have been associated with signifi-
cant infectious relatedmortality post AlloSCT (Mehta et al ASBMT,
2010). We have previously demonstrated the safety and efficacy of
prophylactic liposomal amphotericin B (AMB) for 100 days post
AlloSCT in pediatric recipients (Roman/Cairo et al PBC, 2008).
Although AMB is effective for prophylaxis against IMI post Al-
loSCT, its association with nephrotoxicity and infusion related reac-
tions results in its discontinuation in. 10% of patients. Micafungin,
an echinocandin has been shown to be efficacious against both
Candida spp and Aspergillus spp with minimum toxicity and is
now approved for use as prophylaxis against invasive fungal infec-
tions in patients undergoing AlloSCT. (Pappas et al, 2009).
Methods: We conducted a prospective trial of administering pro-
phylactic AMB (3mg/kg/day) IV from d 0-44 then transitioning to
Micafungin (1mg/kg/day) IV at d 45 until d 100 if \ grade II
AGVHD at d +45. AGVHDprophylaxis were tacrolimus and myco-
phenolate mofetil (n 5 34) as we have previously described (Bhatia/
Cairo et al BBMT, 2009). Those who received CD-34 selected
PBSC (T-depleted) received tacrolimus only (n 5 15). Treatment
success was defined as prevention of IMI prior to day +100 post
AlloSCT.
Result: Median age: 8 yrs (2mo-23yr) Sex:14F, 35M Diagnose-
s:7ALL, 9AML, 6NHL, 1NBL, 6SAA, 1beta-Thal, 1MDS, 9SCD,
1FA, 1ALD, 2SCID, 1PNH, 1Atypical Wolmans, 3HLH. There
were 17CB donors (15-unrelated, 2-related), 16PBSC (15-unrelated,
1-related), 13RBM and 3URBM. The probability of developing $
grade II acute GVHD and extensive chronic GVHD was 12.2%
and 6%, respectively. There were no documented IMI within 100
days post transplantation. There were 7 documented invasive can-
dida infections (ICI). 4 ICI occurred while on AMB prior to switch-
ing to Micafungin, (mean of 21 days post AlloSCT), all infections
resolved in this cohort, the other 2 ICI occurred after switching to
Micafungin (mean of 30 days after switching) with one death due
to ICI. There were no reported side effects attributable to Micafun-
gin or discontinuation due to toxicity.
Conclusion: AlloSCT recipients are at high risk for both ICI and
IMI. Our preliminary data suggests that prophylaxis of AMB (D
0-44) and Micafungin (D 45-100) during the first 100 days post
AlloSCT is both safe and efficacious in preventing IMI. Larger ran-
domized studies are still needed to compare this combination to
other standard antifungal prophylaxis regimens.345
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Background: Hematopoietic Stem Cell Transplant (HSCT) recip-
ients are at risk for fatal bacterial infections during the engraftment
period. Empirical antibiotic(s) at the onset of febrile neutropenia re-
main the standard of care. HSCT recipients began receiving intrave-
nous once daily ceftriaxone at the onset of neutropenia (neutrophils
\1.0) regardless of fever as part of The Ottawa Hospital Blood and
Marrow Outpatient Programme policy from Jan 2009; ‘‘pre-
emptive’’ approach. We examined the impact of this policy on
HSCT recipient outcomes.
Methods: A retrospective ‘‘before-after’’ study was conducted to
compare 2 cohorts [Jan 2008 - Dec 2008 (Empiric strategy) vs. Jan
2009 - Dec 2009 (Pre-emptive strategy)] of patients receiving
HSCT. Baseline characteristics between the groups were compared
with 2 sample tests. Categorical variables and continuous variables
were compared using Chi-squared and Wilcoxan rank-sum tests
respectively.
Results:There were 238 HSCTs performed between Jan 2008 and
Dec 2009 with 127 and 111 in the earlier and later cohorts respec-
tively. Baseline characteristics between the cohorts were similar.
Infection related mortality at 100 days after HSCT and during
the engraftment period were similar with a pre-emptive strategy
compared to an empiric strategy (7.2% vs 10.2%; p 5 0.41 and3.6% vs 7.1%; p 5 0.24) respectively. Further, there were no dif-
ferences in ICU admissions or length of hospital stay. Both micro-
biologically (MDI) and clinically documented infections (CDI)
were reduced (11.7% vs 29.1%;p 5 0.001 and 18.2% vs33.9%;p
5 0.007) with the pre-emptive strategy compared with an empiric
strategy. Importantly, recipients of autologous HSCT appear to
have a lower infection related mortality and reduced infection
related ICU admissions during the engraftment period with the
pre-emptive strategy compared to an empiric strategy (0% vs
6.8%; p 5 0.03 and 2.9% vs 12.2% p 5 0.04). The need for esca-
lation of antimicrobial treatments, resistance pattern of MDIs and
cost of antimicrobial treatment were not different between the two
groups.
Conclusions: The use of once daily intravenous ceftriaxone at the
onset of neutropenia in patients receiving HSCT is safe and effec-
tive particularly in patients receiving autologous HSCT. Further
studies are warranted to study the impact of this ‘‘pre-emptive’’
strategy.346
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The use of psychotropic medications during and following pedi-
atric hematopoietic stem cell transplant (HSCT) is not well de-
scribed. We performed a retrospective review of the prescription
of psychotropic medications during a two year period at our
institution. We report the use of the following medications from
admission to one year post-HSCT: fluoxetine, sertraline, fluvox-
amine, citalopram, trazodone, clonazepam, methylphenidate,
ziprazodone, apiprazole, risperidone, mirtazepine, bupropion,
escitalopram, olanzepine, and paroxetine. During this period 130
patients had a total of 152 transplants. Seventeen patients
(13.1%) were prescribed at least one of the medications investi-
gated. The majority of patients (55.6%) were prescribed more
than one medication. The medications used included: citalopram
(55.6%), risperidone (27.8%), methylphenidate (27.8%), clonaze-
pam (27.8%), trazodone (22.2%), mirtazepine (11.1%), escitalo-
pram (5.6%), and bupropion (5.6%). The timing of the initial
prescription of a psychotropic medication was prior to admission
(47.1%), during the initial transplant admission (29.4%), and 3-6
months post-HSCT (23.5%). Anxiety was the most common indi-
cation for starting a medication (30.3%) followed by depression
(18.2%), sleep disturbance (15.2%), mood stabilization (12.1%), fa-
tigue (9%), and other indication (15.2%). The median duration of
medication use was 116.4 days (range 3-374 days). Medications
were discontinued prior to one year post-HSCT due to symptom
improvement (38.5%), toxicity (7.7%), or patient refusal (11.5%).
34.6% were still on drug at one year post-HSCT and 7.7% died
prior to one year while receiving psychotropic medication. The
median age of patients who received psychotropic medications
was 13.5 years (4-19.6 years) compared to 7.4 years (0.5-22 years)
(p\ 0.0001) in patient who did not receive medications. There was
no significant difference in the sex, type of transplant, underlying
diagnosis, or presence of graft-versus-host disease between the
groups. Psychotropic medications are commonly prescribed in
this group of pediatric HSCT patients particularly in adolescents
and young adults. Further investigation is needed into the psychi-
atric needs of this high-risk population.347
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Background: Increase of CRP, WBC, and inflammatory cytokines
suggest the presence of inflammation but do not necessarily indicate
